4//SEC Filing
Loxam Teri 4
Accession 0001649094-25-000006
CIK 0001649094other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 4:05 PM ET
Size
21.1 KB
Accession
0001649094-25-000006
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Loxam Teri
Director
Transactions
- Sale
Common Stock
2025-01-15$80.46/sh−146$11,747→ 13,279 total - Sale
Common Stock
2025-01-15$82.89/sh−1,136$94,168→ 11,928 total - Sale
Common Stock
2025-01-15$85.29/sh−1,043$88,961→ 9,683 total - Sale
Common Stock
2025-01-15$88.54/sh−529$46,836→ 7,175 total - Sale
Common Stock
2025-01-15$86.26/sh−966$83,324→ 8,717 total - Sale
Common Stock
2025-01-15$83.93/sh−1,202$100,885→ 10,726 total - Exercise/Conversion
Stock Option (right to buy)
2025-01-15−6,250→ 6,250 totalExercise: $22.70Exp: 2032-05-31→ Common Stock (6,250 underlying) - Exercise/Conversion
Common Stock
2025-01-15$22.70/sh+6,250$141,875→ 13,425 total - Sale
Common Stock
2025-01-15$81.53/sh−215$17,530→ 13,064 total - Sale
Common Stock
2025-01-15$87.38/sh−1,013$88,513→ 7,704 total
Footnotes (10)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 18, 2024.
- [F10]Option is fully vested and exercisable.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $80.32 to $80.48. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $81.36 to $81.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price reported is a weighted-average price. The shares were sold at prices ranging from $82.455 to $83.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The price reported is a weighted-average price. The shares were sold at prices ranging from $83.51 to $84.37. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The price reported is a weighted-average price. The shares were sold at prices ranging from $84.83 to $85.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F7]The price reported is a weighted-average price. The shares were sold at prices ranging from $85.89 to $86.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F8]The price reported is a weighted-average price. The shares were sold at prices ranging from $86.89 to $87.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F9]The price reported is a weighted-average price. The shares were sold at prices ranging from $87.915 to $88.91. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Documents
Issuer
Vaxcyte, Inc.
CIK 0001649094
Entity typeother
Related Parties
1- filerCIK 0001829111
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 4:05 PM ET
- Size
- 21.1 KB